相关实验视频

Updated: Jan 7, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

低输入蛋白质组学将vWF确定为Tet2突变造血干细胞扩张的负调节者

Maria Jassinskaja¹, Daniel Bode², Monika Gonka²

¹Centre for Blood Research, York Biomedical Research Institute, Department of Biology, University of York, York YO10 5DD, UK; Lund Stem Cell Center, Division of Molecular Medicine and Gene Therapy, Lund University, Lund 221 84, Sweden.

|December 25, 2025

概括

血造干细胞 (HSC) 中的四甲基甘氨酸2 (TET2) 功能丧失突变改变了蛋白质组,揭示了驱动白血病前HSC扩张的细胞外基质 (ECM) 分子.

科学领域:

血液学血液学血液学
分子生物学分子生物学
癌症研究癌症研究

背景情况:

造血干细胞 (HSC) 对于血液细胞的形成至关重要.
遗传突变,如TET2的功能丧失,可以通过改变HSC自我更新来驱动血液癌症.
在TET2突变性HSC中蛋白质水平的变化仍未得到充分研究.

研究的目的:

在蛋白质水平上全面描述TET2缺乏的HSC的多奥米克景观.
确定调节白血病前HSC扩张的新型分子机制.
探索细胞外矩阵 (ECM) 分子在TET2-突变HSC行为中的作用.

主要方法:

从小鼠模型中对野生类型和TET2缺乏的HSC进行深度多基因分析 (表观基因组,转录基因组,蛋白质组).
基于低输入质谱 (MS) 的最先进的多重化蛋白质组学.
使用ECM功能化水凝进行功能性测试,以评估HSC扩张.

主要成果:

蛋白质基因分析揭示了在白血病前的HSC中以前未知的分子过程.
TET2缺陷失调的细胞外矩阵 (ECM) 分子.
实现了野生类型和TET2缺陷HSC的精确分层,超过了转录基因方法.
具有ECM功能的水凝选择性地增强了TET2突变HCs的扩张.

结论:

这项研究提供了TET2突变HSC的全面分子特征.
调节失调的ECM分子在调节致病性HSCs的自我更新方面发挥着至关重要的,以前未被认可的作用.
针对ECM相互作用可能为TET2突变骨髓性恶性瘤提供新的治疗策略.

关键词:

CP:干细胞研究.在TET2的基础上.生物物理学的生物物理学.细胞外矩阵是细胞外矩阵.造血干细胞是血液形成的干细胞.多种主题的多种主题.物理生物学物理生物学蛋白质组学蛋白质组学它是自我更新的.单细胞生物学单细胞生物学

更多相关视频

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

相关概念视频

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...